Skip to main content
. Author manuscript; available in PMC: 2020 Jun 3.
Published in final edited form as: Circ Cardiovasc Qual Outcomes. 2012 Nov 13;5(6):750–758. doi: 10.1161/CIRCOUTCOMES.112.967406

Table 3.

Results of Survival Analyses

Hazard Ratio
(95% CI) 		P-value
Primary end point
 Unadjusted 0.64 (0.37-1.12) 0.12
 Adjusted for stratification variables (age, gender, lipid lowering medications) – primary analysis 0.52 (0.29-0.92) 0.025
 Adjusted for stratification variables + education, baseline CESD 0.54 (0.30-0.98) 0.04
 Including events in non-reenrolled subjects during hiatus and phase 2, adjusted for stratification variables 0.57 (0.34-0.96) 0.03
Secondary end point
 Unadjusted 0.77 (0.52-1.15) 0.21
 Adjusted for stratification variables (age, gender, lipid lowering medications) 0.76 (0.51-1.13) 0.17
 Adjusted for stratification variables + education, baseline CESD 0.82 (0.54-1.24) 0.36